Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the monarchE trial, which evaluated abemaciclib plus endocrine therapy for HR+, HER2 negative, node positive, high-risk early breast cancer.
Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma
WASHINGTON (dpa-AFX) - Biopharmaceutical company Novavax, Inc. (NVAX), which advances protein-based vaccines with its novel Matrix-M adjuvant, announced on Monday that it has signed a three-year